You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePapaverine
Accession NumberDB01113  (APRD00628, DB07725)
TypeSmall Molecule
GroupsApproved
DescriptionAn alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]
Structure
Thumb
Synonyms
Mesotina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Papaverine Hydrochloride Injection USPLiquid65 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1951-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Papaverine HydrochlorideInjection, solution30 mg/mLIntravenousAmerican Regent, Inc.1995-09-01Not applicableUs
Papaverine HydrochlorideInjection, solution30 mg/mLIntravenousAmerican Regent, Inc.1995-09-01Not applicableUs
International Brands
NameCompany
AlapavNot Available
AlbatranNot Available
ArtegodanNot Available
CardioverinaNot Available
CerebidNot Available
CerespanNot Available
DelapavNot Available
DilavesNot Available
DispamilNot Available
DrapavelNot Available
DurapavNot Available
DynovasNot Available
MesotinaNot Available
MyobidNot Available
OptenylNot Available
PameionNot Available
PamelonNot Available
PanergonNot Available
PapaconNot Available
PapaleaseNot Available
PapaversanNot Available
Papital T.R.Not Available
Paptial T.R.Not Available
PavabidNot Available
PavacapNot Available
PavacenNot Available
PavadelNot Available
PavagenNot Available
PavakeyNot Available
PavasedNot Available
PavatestNot Available
PaverolanNot Available
PaveronNot Available
PavnellNot Available
Qua BidNot Available
Ro-PapavNot Available
TherapavNot Available
VasalNot Available
Vaso-PavNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Papaverine Codecarboxylate
56896-69-6
Thumb
  • InChI Key: VTJFMXLVZKZSGE-UHFFFAOYSA-N
  • Monoisotopic Mass: 586.171631734
  • Average Mass: 586.5269
DBSALT000784
Papaverine Hydrochloride
61-25-6
Thumb
  • InChI Key: UOTMYNBWXDUBNX-UHFFFAOYSA-N
  • Monoisotopic Mass: 375.123735904
  • Average Mass: 375.846
DBSALT000412
Categories
UNIIDAA13NKG2Q
CAS number58-74-2
WeightAverage: 339.385
Monoisotopic: 339.147058165
Chemical FormulaC20H21NO4
InChI KeyXQYZDYMELSJDRZ-UHFFFAOYSA-N
InChI
InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
SMILES
COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Pharmacology
IndicationFor the treatment of impotence and vasospasms.
Structured Indications Not Available
PharmacodynamicsPapaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.
Mechanism of actionPerhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.
TargetKindPharmacological actionActionsOrganismUniProt ID
cAMP-specific 3',5'-cyclic phosphodiesterase 4BProteinyes
inhibitor
HumanQ07343 details
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AProteinunknown
inhibitor
HumanQ9Y233 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding~90%
MetabolismNot Available
Route of eliminationNot Available
Half life0.5-2 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Papaverine is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.Approved
AliskirenThe risk or severity of adverse effects can be increased when Papaverine is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Papaverine is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Papaverine.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Papaverine is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Papaverine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Papaverine is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Papaverine is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Papaverine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Papaverine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Papaverine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Papaverine is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Papaverine is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Papaverine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Papaverine.Experimental
BarbitalBarbital may increase the hypotensive activities of Papaverine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.Approved
BepridilThe risk or severity of adverse effects can be increased when Papaverine is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Papaverine.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Papaverine is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Papaverine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Papaverine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Papaverine is combined with Bupivacaine.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Papaverine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Papaverine is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Papaverine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Papaverine is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Papaverine is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Papaverine.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Papaverine is combined with Conivaptan.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Papaverine is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Papaverine is combined with Diclofenamide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Papaverine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.Approved
DuloxetinePapaverine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Papaverine is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Papaverine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Papaverine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Papaverine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Papaverine is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Papaverine is combined with Fimasartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Papaverine is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Papaverine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Papaverine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Papaverine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Papaverine is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Papaverine is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Papaverine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Papaverine is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine.Approved
IndoraminThe risk or severity of adverse effects can be increased when Papaverine is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Papaverine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Papaverine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Papaverine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Papaverine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Papaverine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Papaverine.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Papaverine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Papaverine is combined with Levobupivacaine.Approved
LevodopaPapaverine may increase the hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Papaverine is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Papaverine is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Papaverine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Papaverine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Papaverine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Papaverine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Papaverine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Papaverine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Papaverine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Papaverine.Approved
MorphineThe risk or severity of adverse effects can be increased when Papaverine is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Papaverine is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Papaverine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.Approved
NebivololThe risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Papaverine is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Papaverine.Approved
NicorandilNicorandil may increase the hypotensive activities of Papaverine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Papaverine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Papaverine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Papaverine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Papaverine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Papaverine is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Papaverine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Papaverine is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Papaverine is combined with Paclitaxel.Approved, Vet Approved
PenbutololThe risk or severity of adverse effects can be increased when Papaverine is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Papaverine.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Papaverine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Papaverine is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Papaverine.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Papaverine is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Papaverine is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Papaverine is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Papaverine is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.Approved
PrimidonePrimidone may increase the hypotensive activities of Papaverine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Papaverine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Papaverine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Papaverine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Papaverine is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Papaverine is combined with Riociguat.Approved
RisperidonePapaverine may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Papaverine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Papaverine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Papaverine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Papaverine is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Papaverine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Papaverine is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Papaverine is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Papaverine is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Papaverine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Papaverine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Papaverine is combined with Sufentanil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Papaverine is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Papaverine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Papaverine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Papaverine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Papaverine is combined with Thioridazine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Papaverine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Papaverine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Papaverine is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Papaverine.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Papaverine is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Papaverine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Tang Y, Luan J, Zhang X: Accelerating tissue expansion by application of topical papaverine cream. Plast Reconstr Surg. 2004 Oct;114(5):1166-9. [PubMed:15457029 ]
  2. Liu JK, Couldwell WT: Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;2(2):124-32. [PubMed:16159054 ]
  3. Takeuchi K, Sakamoto S, Nagayoshi Y, Nishizawa H, Matsubara J: Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2004 Nov;26(5):956-9. [PubMed:15519189 ]
External Links
ATC CodesG04BE02G04BE52A03AD01
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9633
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.5389
P-glycoprotein inhibitor INon-inhibitor0.6485
P-glycoprotein inhibitor IINon-inhibitor0.8005
Renal organic cation transporterNon-inhibitor0.7229
CYP450 2C9 substrateNon-substrate0.796
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6263
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8448
CYP450 2C19 inhibitorInhibitor0.778
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8558
Ames testNon AMES toxic0.689
CarcinogenicityNon-carcinogens0.9503
BiodegradationNot ready biodegradable0.9262
Rat acute toxicity2.9877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9329
hERG inhibition (predictor II)Non-inhibitor0.7274
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous30 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous65 mg
Prices
Unit descriptionCostUnit
Papaverine 150 mg capsule sa1.86USD capsule
Papaverine 60 mg/2 ml vial1.68USD ml
Papaverine hcl powder0.76USD g
Para-time 150 mg capsule sa0.23USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226 (dec) °CPhysProp
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0129 mg/mLALOGPS
logP4.19ALOGPS
logP3.08ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)6.03ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area49.81 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity95.52 m3·mol-1ChemAxon
Polarizability36.57 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub ClassBenzylisoquinolines
Direct ParentBenzylisoquinolines
Alternative Parents
Substituents
  • Benzylisoquinoline
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:
PDE4B
Uniprot ID:
Q07343
Molecular Weight:
83342.695 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J: Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. [PubMed:12646997 ]
  4. Zhu S, Gan Z, Li Z, Liu Y, Yang X, Deng P, Xie Y, Yu M, Liao H, Zhao Y, Zhao L, Liao F: The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal Chim Acta. 2009 Mar 16;636(1):105-10. doi: 10.1016/j.aca.2009.01.035. Epub 2009 Jan 22. [PubMed:19231363 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR: Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl). 2009 May;203(4):723-35. doi: 10.1007/s00213-008-1419-x. Epub 2008 Dec 9. [PubMed:19066855 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23